Cardiovascular registry research comes of age
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No matter how beautiful the strategy, you should occasionally look at the results.
Winston Churchill
Registry research is gaining increasing visibility within cardiovascular medicine. Randomised controlled trials (RCTs) are rightly at the top of the hierarchy of evidence for determining clinical efficacy. However, the characteristic that makes the RCT so powerful in establishing internal validitydcontroldlimits the ability to provide a comprehensive picture of clinical medicine as it is practised. As in the Churchill quote above, RCTs may be able to provide the basis for the most 'beautiful' management strategies, but determining how these strategies work in the 'real world' is critical. In addition to these limitations in external validity, practical problems such as cost, time horizon and breadth of questions leave a clear need for many types of observational research. Registries across the globe are actively examining many aspects of this need. As with all study types, critical assessment of the structure, strengths and weaknesses of registries is necessary in order to gain an appropriate perspective of where this research fits into the broad picture of cardiovascular medicine. To this end, Heart will publish a new series of articles describing some of the most important registries of patients with acute coronary syndrome and other cardiovascular disorders.
ROLE OF REGISTRIES
How can registry research contribute to filling the knowledge gap? In his 2000 editorial entitled 'Are data from clinical registries of any value', Alpert articulated a well-reasoned affirmative answer to this question. 1 Gitt and colleagues recently published an updated defence of cardiac registries in evidence-based medicine. 2 Briefly, registries have multiple purposes. First, they can be designed to assess the translation of information from an RCT into clinical practice. For instance, many therapeutic strategiesdreperfusion, aspirin, b blockers and angiotensin converting enzyme inhibitorsdhave been shown to reduce mortality in patients with STsegment elevation myocardial infarction. However, registries have been instrumental in demonstrating low adoption rates of these strategies, 3e5 in identifying potential strategies to deal with them 6 and in showing improvement over time. 7 8 Second, registries can evaluate how the efficacy of a treatment extends to populations not included, or not well represented, in the RCTs. Patients in clinical trials are not representative of the populationdeither in baseline characteristics or in outcomes. 9 10 Also, large academic tertiary care hospitals are more likely to participate in RCTs. While this bias may be minimal for simple treatments such as administration of a pharmaceutical agent, any evaluation of a more complex intervention, such as PCI, may very well be influenced by operator and hospital experience. 11 Third, registries can assess longer-term risks than clinical trials. Owing to the high expense of RCTs, the time horizon of the experimental phase rarely exceeds 3e5 years. The impact of a therapeutic strategy over a longer period may be critical for a true assessment of riskebenefit, and certainly, for costebenefit analyses.
Fourth, owing to the ability to follow-up large groups of patients for extended time periods, registries can often identify low incidence but important risks that RCTs would not. For instance, cardiovascular mortality for treatment of non-cardiovascular conditions, such as non-steroidal antiinflammatory agents for rheumatological conditions, 12 are often difficult to ascertain in RCTs.
Fifth, registries can answer certain questions not easily addressed by RCTs. For instance, identifying optimal timing of intervention in patients with unstable angina or non-ST-segment elevation myocardial infarction was dealt with more feasibly in a 'real-world' registry 13 than the controlled environment of an RCT.
A sixth area of potential registry impact is only emerging with the improved rigor of registry design and implementationd registries that reliably capture a defined population can be used for monitoring incidence of disease entities and evaluating potential aetiologies. For instance, the MINAP study includes all acute cardiac care hospitals in England and Wales. Trends in hospital admissions for acute coronary syndrome can reliably monitor trends in incidence for the population.
LIMITATIONS OF REGISTRIES
Registries certainly have a number of limitations and will never replace RCTs for determining the efficacy of management strategies in those patients meeting inclusion criteria predefined by the trialists. Owing to the lack of experimental control in registry populations, internal validity can be significantly affected by indication biasdfor example, an association between a treatment and an improved outcome might be due to higher-risk patients not receiving the treatment.
Second, external validity of registries can also be limited by selection bias just as with RCTs. Most registries do not capture 100% of the population with a specific conditiondboth through limited participation of sites (eg, hospitals) and incomplete capture of patients within a site. 14 15 Even adequate representation of a defined population, such as England and Wales, does not guarantee validity for other populations around the world with different patient groups and different health systems.
Third, feasibility constraints limit the amount of information obtained for each participant. Collecting even the basic demographic and clinical data on patients creates significant administrative burden for the sites. An appropriate balance between completeness and feasibility needs to be obtained.
Fourth, the quality of the data collection is critical in limiting bias. Missing data can be a significant challenge as the assumption that data are missing at random is often questionable.
Fifth, multiple analyses in attempts to identify associations within a given dataset raise caution over the interpretation of results.
Sixth, as is well known positive associations are more likely to end in publication than negative ones, resulting in a publication bias. Thus, in order to provide credible evidence, just as with RCTs, investigators need to understand and deal with these limitations.
Fortunately, with the appropriate scientific rigor, steps can be taken to improve the quality of registries and are listed in table 1.
REGISTRIES IN ACUTE CORONARY SYNDROME
Acute coronary syndrome is well represented in registry research. Three of the registries that will be featured in Heart are compared in 
FUTURE CONSIDERATIONS
Linkage of datasets is currently being exploited. Horizontal linkage of clinical datasets will enable a sharing of rich clinical information with subsets of participants with blood samples. Vertical linkages will enable better elucidation of the patient journeydsharing information from primary care datasets with those of disease-specific datasets, such as acute coronary syndrome. Ultimately, the Holy Grail of registries will harness the vast information available in electronic health records to truly study a representative sample of the population with coordinated horizontal and vertically rich clinical information.
The quality of RCTs has improved dramatically over the past four decades with institution of standardised, rigorous protocols. In much the same fashion, improved design, collection and analytical 
